RAPT Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . RAPT Therapeutics
RAPT Stock  USD 1.08  0.03  2.86%   
RAPT Therapeutics financial statements provide useful quarterly and yearly information to potential RAPT Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on RAPT Therapeutics financial statements helps investors assess RAPT Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting RAPT Therapeutics' valuation are summarized below:
Gross Profit
1.5 M
Market Capitalization
37.8 M
Enterprise Value Revenue
677.3673
Earnings Share
(2.78)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty trending fundamental ratios for RAPT Therapeutics that can be evaluated and compared over time across competitors. All traders should check out RAPT Therapeutics' recent fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 556.1 M in 2024. Enterprise Value is likely to drop to about 522.4 M in 2024

RAPT Therapeutics Total Revenue

1.53 Million

Check RAPT Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RAPT Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 952.3 K, Interest Expense of 1.3 M or Selling General Administrative of 14.6 M, as well as many indicators such as Price To Sales Ratio of 208, Dividend Yield of 0.0 or PTB Ratio of 6.8. RAPT financial statements analysis is a perfect complement when working with RAPT Therapeutics Valuation or Volatility modules.
  
Check out the analysis of RAPT Therapeutics Correlation against competitors.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

RAPT Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets151.1 M173.3 M97.7 M
Slightly volatile
Other Current Liabilities12.4 M11.8 M4.2 M
Slightly volatile
Total Current Liabilities11.7 M21.8 M7.3 M
Slightly volatile
Other Liabilities2.2 M3.1 M1.6 M
Slightly volatile
Property Plant And Equipment Net5.1 M7.7 M3.4 M
Slightly volatile
Accounts Payable2.7 M5.2 M1.8 M
Slightly volatile
Cash37 M47.5 M46.2 M
Pretty Stable
Non Current Assets Total7.1 M11.5 M4.5 M
Slightly volatile
Non Currrent Assets Other4.1 M3.9 M1.2 M
Slightly volatile
Other Assets0.951.0667.5 K
Slightly volatile
Cash And Short Term Investments141.1 M158.9 M91.4 M
Slightly volatile
Common Stock Total Equity2.4 K3.5 K1.7 K
Slightly volatile
Common Stock Shares Outstanding27.7 M38.3 M20.3 M
Slightly volatile
Liabilities And Stockholders Equity151.1 M173.3 M97.7 M
Slightly volatile
Non Current Liabilities Total4.2 M4.5 M60.1 M
Slightly volatile
Capital Surpluse740.3 M705 M218.2 M
Slightly volatile
Other Current Assets4.2 M2.9 M2.4 M
Slightly volatile
Other Stockholder Equity375.9 M631.6 M195.8 M
Slightly volatile
Total Liabilities23.3 M26.3 M67.8 M
Slightly volatile
Property Plant And Equipment Gross17.9 M17 M4.9 M
Slightly volatile
Total Current Assets144.1 M161.8 M93.2 M
Slightly volatile
Net Working Capital132.4 M139.9 M86 M
Slightly volatile
Common Stock2.5 K3.5 K1.7 K
Slightly volatile
Property Plant Equipment2.4 M2.3 M2.4 M
Slightly volatile
Capital Stock2.8 K3.5 K2.3 K
Slightly volatile
Current Deferred Revenue868.7 K914.4 K3.2 M
Slightly volatile
Short Term Debt5.3 M4.9 M4.1 M
Slightly volatile
Short Term Investments157.8 M111.4 M106.5 M
Slightly volatile
Deferred Long Term Liabilities2.3 M2.4 M2.9 M
Slightly volatile
Short and Long Term Debt Total6.4 M6.9 M8.7 M
Slightly volatile
Non Current Liabilities Other5.5 M6.1 M6.7 M
Slightly volatile

RAPT Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization952.3 K1.2 M1.3 M
Slightly volatile
Selling General Administrative14.6 M26.1 M8.9 M
Slightly volatile
Other Operating Expenses71.6 M127.1 M48.8 M
Slightly volatile
Research Development57 M101 M39.9 M
Slightly volatile
Total Operating Expenses71.6 M127.1 M48.8 M
Slightly volatile
Reconciled Depreciation944.2 K1.1 M1.3 M
Slightly volatile
Total Other Income Expense Net10.8 M10.3 M1.9 M
Slightly volatile
Tax Provision170.1 K179.1 K555.8 K
Slightly volatile
Cost Of Revenue2.4 M3.6 M1.6 M
Slightly volatile
Non Operating Income Net Other1.2 M2.3 M1.3 M
Very volatile
Selling And Marketing Expenses2.8 M3.2 M3.5 M
Slightly volatile

RAPT Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock158.4 M150.9 M58.5 M
Slightly volatile
Stock Based Compensation17.9 M17.1 M4.9 M
Slightly volatile
Begin Period Cash Flow36.8 M38.9 M45.2 M
Pretty Stable
Other Cashflows From Financing Activities1.4 M1.4 M23.3 M
Slightly volatile
Depreciation952.3 K1.2 M1.3 M
Slightly volatile
Capital Expenditures986.9 K1.1 M1.2 M
Very volatile
Total Cash From Financing Activities1.4 M1.4 M46.3 M
Slightly volatile
End Period Cash Flow37 M47.5 M46.2 M
Pretty Stable
Change To Netincome14.4 M13.7 M4.6 M
Slightly volatile
Issuance Of Capital Stock95.6 M75 M69.3 M
Slightly volatile
Other Cashflows From Investing Activities36 K40.5 K44.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio208380154
Slightly volatile
Stock Based Compensation To Revenue6.976.642.8364
Slightly volatile
Capex To Depreciation1.120.92520.9306
Very volatile
EV To Sales200362147
Slightly volatile
Payables Turnover0.950.68611.0226
Slightly volatile
Sales General And Administrative To Revenue12.5311.934.6522
Slightly volatile
Research And Ddevelopement To Revenue41.5139.5415.9439
Slightly volatile
Capex To Revenue0.520.50.176
Slightly volatile
Cash Per Share3.874.14374.0483
Slightly volatile
Days Payables Outstanding377532399
Slightly volatile
Income Quality0.950.83090.8974
Slightly volatile
Current Ratio14.567.40914.0816
Pretty Stable
Graham Number12.6116.21414.7196
Slightly volatile
Capex Per Share0.02790.02930.0661
Slightly volatile
Revenue Per Share0.05130.0540.1726
Slightly volatile
Interest Debt Per Share0.06070.06394.0374
Slightly volatile
Debt To Assets0.01340.01411.1544
Slightly volatile
Days Of Payables Outstanding377532399
Slightly volatile
Ebt Per Ebit1.070.91920.9888
Very volatile
Long Term Debt To Capitalization1.882.112.3024
Slightly volatile
Total Debt To Capitalization0.01560.01641.2582
Slightly volatile
Quick Ratio14.567.40914.0816
Pretty Stable
Net Income Per E B T1.11.121.0238
Slightly volatile
Cash Ratio2.072.174310.0498
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.01161.0426
Very volatile
Fixed Asset Turnover0.180.191.3681
Slightly volatile
Debt Ratio0.01340.01411.1544
Slightly volatile
Price Sales Ratio208380154
Slightly volatile
Asset Turnover0.00630.00660.0336
Slightly volatile

RAPT Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap556.1 M905.4 M665.2 M
Slightly volatile
Enterprise Value522.4 M883.8 M605.1 M
Slightly volatile

RAPT Fundamental Market Drivers

Cash And Short Term Investments158.9 M

RAPT Upcoming Events

12th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About RAPT Therapeutics Financial Statements

RAPT Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although RAPT Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in RAPT Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on RAPT Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue914.4 K868.7 K
Cost Of Revenue3.6 M2.4 M
Stock Based Compensation To Revenue 6.64  6.97 
Sales General And Administrative To Revenue 11.93  12.53 
Research And Ddevelopement To Revenue 39.54  41.51 
Capex To Revenue 0.50  0.52 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(64.61)(61.38)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY